Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever

The piece highlights three buy-and-hold income names: AbbVie (market cap ~ $345B) with a forward dividend yield of 3.17% and 52 consecutive years of dividend increases, relying on new growth from Rinvoq and Skyrizi after Humira biosimilar pressure; Brookfield Infrastructure (BIP/BIPC/BEP) offering distribution yields of ~5.12% (LP) and 4.04% (corporate), 15 years of consecutive increases and a targeted 5–9% annual distribution growth driven by acquisitions, operational improvements and asset recycling; and Verizon (VZ) with a 6.27% forward dividend yield, an 18-year streak of increases, a forward P/E of 9.3 and a planned $20 billion all-cash acquisition of Frontier to expand its fiber footprint. The article frames these names as dependable passive-income plays rather than market-moving news.

Analysis

Market structure: The short list (ABBV, BIP/BIPC, VZ) benefits income-focused investors and private-asset managers; AbbVie’s $345B scale and established dividend (3.17%) preserve pricing power in branded biologics while Brookfield captures long-duration cash flows (BIP yield ~5%+). Verizon’s 6.27% yield and planned $20B Frontier purchase shift telecom economics toward fiber scale, pressuring smaller ISPs and raising fixed-cost amortization for legacy mobile players. Cross-asset: sustained high cash yields widen spread vs. 10-year Treasuries (recently in the low-to-mid hundreds of bps), likely muting rate-sensitive REITs/utilities and compressing high-duration equity multiples; credit spreads for leveraged acquirers (VZ) deserve watch for 100–200bp widening risk.

Risk assessment: Tail risks include regulatory action on drug pricing or M&A blockers for VZ/Frontier, a deeper biosimilar wave hitting AbbVie’s margins, or macro shock pushing funding costs >200bp higher within 6–12 months. Near-term (days–months) volatility centers on deal approvals and quarterly FCF cadence; medium/long-term (1–5 years) outcomes depend on drug launches (Rinvoq/Skyrizi) and Brookfield’s asset rotation execution. Hidden dependencies: Brookfield’s distribution growth assumes asset sales; a frozen M&A market stalls that compounding. Catalysts: FDA outcomes, DOJ/FTC M&A rulings, and oil/gas price swings influencing pipeline/utility cash flows.

Trade implications: Direct: establish tactical income-sized positions—ABBV and BIPC/BIP—for 2–4% portfolio weights with staggered buys over 6 months to average entry; favor BIPC if tax/K-1 is an issue. Pair: long BIP (or BIPC) vs short domestic utility ETF (XLU) by 1:1 notional to capture wider distribution growth guidance (5–9%). Options: sell 45–60 day covered calls on VZ to harvest yield and buy 6–9 month puts on ABBV (10% OTM) as cheap tail insurance around biosimilar news. Rotate 5–10% from growth into these income names if 2025 EPS growth expectations slip by >10%.

Contrarian angles: Consensus underestimates integration/execution risk—VZ’s Frontier deal may take 12–24 months to realize synergies and could require >$3–5bn capex reforecast, making near-term yield fragile. AbbVie’s dividend safety hinges on successful ramp of Rinvoq/Skyrizi; a 20% miss in peak sales would pressure payouts or buybacks. Brookfield is priced for steady asset rotation; a 6–9 month liquidity squeeze in secondary markets would cap distribution growth below its 5% floor. Consider small, liquid hedges (short single-name credit default swaps or buying index protection) if any one name exceeds 5% portfolio weight within 3 months.

Key Decisions for Investors

• Establish a 2–3% long position in ABBV (ABBV) using staggered buys over 3–6 months; add 10% notional of the ABBV position in 6–9 month 10% OTM puts as tail protection against biosimilar revenue misses or regulatory shocks.
• Allocate 2–4% to Brookfield Infrastructure via BIPC if K‑1 tax exposure is undesirable, or BIP for a higher yield; size so that combined Brookfield exposure does not exceed 4% of portfolio and trim if distributions are cut or if credit spreads widen >150bps in 30 days.
• Buy a 3% weight in VZ, fund by reducing growth tech exposure by 3–5%; sell 45–60 day covered calls to raise effective yield and protect downside, and reduce by 50% if the Frontier deal fails regulatory approval within 12 months.
• Construct a pair trade: long BIP/BIPC (2%) vs short XLU (2%) to play Brookfield’s distribution growth (5–9% guidance) versus regulated utility stagnation; exit if BIP total return underperforms XLU by >300bps over a rolling 6-month period.